Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035169 | 0.91 | PPARG (0.43) | PPARGFABP4FABP5MCL1CHRM1 | |
| SCHEMBL6034930 | 0.90 | PPARG (0.47) | PPARGFABP4FABP5PDE4DALDH1A1 | |
| SCHEMBL6034591 | 0.87 | PPARG (0.51) | PPARGFABP4FABP5PDE4DSCN9A | |
| SCHEMBL6217238 | 0.85 | PPARG (0.37) | PPARGMCL1 | |
| SCHEMBL6036165 | 0.82 | PPARG (0.46) | PPARGFABP4FABP5SCN9AALDH1A1 | |
| SCHEMBL6036096 | 0.82 | PPARG (0.47) | PPARGPDE4DSCN9AALDH1A1 | |
| SCHEMBL6035646 | 0.81 | PPARG (0.45) | PPARGPDE4DSCN9AALDH1A1TAAR1 | |
| SCHEMBL6036343 | 0.81 | PPARG (0.45) | PPARGSCN9ACHRM1ALDH1A1TAAR1 | |
| SCHEMBL6035238 | 0.81 | MAPT (0.40) | PPARGSCN9AALDH1A1 | |
| SCHEMBL6035546 | 0.80 | PPARG (0.48) | PPARGSCN9AALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARG 1037/4885FABP4 279/4885FABP5 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.